ArticleNature communications2025
Reaching elimination of onchocerciasis transmission with long-term vector control and ivermectin treatment in Togo.
Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Modelling anti-Ov16 seroprevalence for the control and elimination of onchocerciasis.Nature communications · 2026Article
- Spatial and seasonal dynamics ofParasite epidemiology and control · 2026Article
- HISTONCHO: A dataset of intervention histories for onchocerciasis control & elimination in sub-Saharan Africa.Scientific data · 2026Article
- Modelling the effects of immigration on the re-introduction of onchocerciasis.Parasites & vectors · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
The Onchocerciasis Control Programme in West Africa implemented vector control (VC) and ivermectin mass drug administration (MDA) to eliminate blindness, intensifying efforts in Special Intervention Zones (SIZ). Togo aims to eliminate onchocerciasis transmission (EOT) by 2030. We use the EPIONCHO-IBM model to project microfilarial prevalence trends across Togo's five regions by SIZ status, MDA coverage (65%-80%) and VC efficacy (60%-100%). We compare projections with prevalence surveys (400 villages, 1970-2017) stratified by hypoendemic, mesoendemic, hyperendemic, and holoendemic baseline endemicity, and calculate EOT probabilities for 2024, 2027, and 2030. Combined VC and MDA reduced prevalence nationwide. After cessation of VC, prevalence continued to decline in hypo-to-mesoendemic areas under annual MDA, while hyperendemic areas required biannual MDA. In holoendemic areas, prevalence rebounded even with biannual MDA, indicating that alternative strategies are needed. EPIONCHO-IBM reproduces Togo's onchocerciasis trends throughout five decades of intervention and provides a transferable framework to guide policy towards 2030 goals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.